Close Menu

Thermo Fisher Scientific

Seer will be able to offer its Proteograph Product Suite for sale with several of the two companies' mass spectrometers.

The agency identified three tests potentially impacted by known mutations, and said it will continue to monitor authorized assays.

Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

The PCR-based kit allows laboratories to test for the diseases, which share clinical symptoms, in approximately three hours.

The company now expects organic revenues to grow 40 percent year over year in Q4, driven by its base business and sales related to the COVID-19 response.

Called direct infusion–shotgun proteome analysis, the approach uses ion mobility in place of liquid chromatography to enable higher-throughput experiments.

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

The firm reported $2 billion in third-quarter revenues related to the COVID-19 response, accounting for 23 percent of its overall revenues.

The company reported net income of $1.93 billion, or $4.84 per share, compared to $760 million, or $1.89 per share, for the year-ago quarter.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.